Recipient Pre-operative Preparation
Admission Checklist
Laboratory & Investigations
- Blood group confirmation + crossmatch with donor sample
- FBC, U&E, creatinine, LFTs, coagulation screen
- Virology screen: CMV, EBV, HBV, HCV, HIV, Toxoplasma, VZV
- MSU / urine C&S
- ECG and CXR (cardiac clearance)
- ECHO if recent cardiovascular history
Clinical Actions
- Haemodialysis if hyperkalaemic (K⁺ >5.5 mmol/L) — day of surgery, to prevent intraoperative arrhythmia
- Pre-hydration: 1 L NaCl 0.9% at call to theatre (promotes immediate graft perfusion)
- NBM 6 hours solids / 2 hours clear fluids
- Informed consent documented
- ID band, allergy band, VTE risk assessment
- Surgical site preparation and chlorhexidine wash
Immunosuppression Induction
- Basiliximab (Simulect): IL-2 receptor antagonist; 20 mg IV Day 0 (intraoperatively) + 20 mg Day 4; standard low-to-moderate risk recipients
- ATG (Anti-Thymocyte Globulin / Thymoglobulin): T-cell depleting; used for sensitised recipients, high PRA, re-transplants, DCD donors; higher infection risk
- Methylprednisolone: 500 mg IV intraoperatively then taper post-op
Surgical Procedure
- Heterotopic placement: Transplanted kidney placed in iliac fossa (NOT in native kidney position); right iliac fossa preferred — iliac vessels more accessible for anastomosis
- Vascular anastomoses: Renal artery to external iliac artery; renal vein to external iliac vein
- Ureteroneocystostomy: Donor ureter inserted into bladder; ureteric stent placed (removed at 4–6 weeks cystoscopically)
- Native kidneys left in situ unless causing hypertension or recurrent infections
Post-operative Monitoring (PACU / HDU)
⚠
Critical Nursing Parameter: Hourly Urine Output
This is the single most important metric in immediate post-transplant care. Document and report every hour. Target: >1 mL/kg/h for immediate graft function. Any sudden drop requires immediate clinical review.
Graft Function Categories
- Immediate Graft Function (IGF): Urine output >1 mL/kg/h within hours; creatinine falling by 24–48h
- Slow Graft Function: Functioning but creatinine falling slowly; no dialysis needed
- Delayed Graft Function (DGF): Dialysis required within first 7 days; associated with DCD donors, prolonged cold ischaemia, ATN
Fluid Management Protocol
- Replace urine output mL for mL with NaCl 0.9% via IV infusion + 30–50 mL/h insensible loss replacement
- Avoid hypovolaemia — graft very sensitive to under-perfusion in first 24 h
- CVP target 8–12 cmH₂O or MAP >70 mmHg
- Restrict fluid only if oliguria confirmed after ruling out obstruction and hypovolaemia
Drains & Catheters
- Foley catheter: 1–2 weeks post-op — protects ureteroneocystostomy anastomosis; irrigate if clots, record UO hourly
- Jackson-Pratt (JP) drain: Placed in iliac fossa; serosanguinous output expected; drain creatinine level if urine leak suspected
- Haematoma: frank blood in drain → surgical review
- Lymphocele: watery clear drain output persisting >7 days
Hourly Monitoring Parameters
| Parameter | Target / Action | Frequency |
|---|
| Urine output | >1 mL/kg/h; alert if <0.5 mL/kg/h for 2h | Hourly |
| Blood pressure | MAP >70 mmHg; SBP 120–150 mmHg | Hourly (q30 min first 4h) |
| Temperature | <38.0°C; fever → cultures + review immunosuppression | 4-hourly |
| Serum creatinine | Trending down (IGF) or monitoring DGF | Daily × 7 days, then alternate days |
| Electrolytes (K⁺, Na⁺) | K⁺ <5.5; high UO may cause hypokalaemia | Daily |
| Tacrolimus trough | 8–12 ng/mL early post-op | Daily × 2 weeks |
| Jackson-Pratt drain output | Decreasing serosanguinous; nil frank blood | Every 4h first 24h |
| Graft site palpation | Soft, non-tender; hard/tender → investigate rejection/haematoma | Each shift |
Induction Therapy
Basiliximab (Simulect)
- Mechanism: IL-2 receptor (CD25) antagonist — prevents T-cell proliferation without T-cell depletion
- Dosing: 20 mg IV on Day 0 (within 2h of reperfusion) + 20 mg IV on Day 4
- Indication: Standard risk recipients, low PRA, first transplant
- Adverse effects: Generally well-tolerated; rare anaphylaxis
- Nursing: Administer over 20–30 min; have resuscitation available
ATG (Thymoglobulin / Anti-Thymocyte Globulin)
- Mechanism: Polyclonal antibody causing T-cell depletion
- Indication: High PRA, re-transplants, sensitised recipients, DCD donors, high-risk of rejection
- Dosing: 1.5 mg/kg/day IV × 3–5 days (dose adjusted to WBC/platelet count)
- SE: Infusion reactions (fever, rigors, thrombocytopenia, leucopenia), serum sickness, increased infection risk
- Nursing: Premedicate with hydrocortisone + chlorphenamine + paracetamol; administer via central line over ≥4h; daily FBC
Maintenance Triple Therapy
ⓘ
Standard Protocol: Tacrolimus + Mycophenolate Mofetil (MMF) + Prednisolone — this combination is the global standard of care in renal transplantation.
Drug Reference — Maintenance Immunosuppression
| Drug | Class/Mechanism | Dose & Levels | Key Side Effects | Nursing Points |
|---|
| Tacrolimus (Prograf / Advagraf) |
CNI — calcineurin inhibitor; inhibits IL-2 transcription |
Trough (C0): 8–12 ng/mL early → 5–8 ng/mL late; individualised |
Nephrotoxicity, new-onset DM (NODAT), neurotoxicity (tremor, headache), hypertension, hair loss, hyperkalemia |
Daily trough level before AM dose; same formulation every time; never crush Advagraf (extended release); report tremor/confusion |
| Mycophenolate Mofetil (MMF / CellCept) |
Antiproliferative — inhibits inosine monophosphate dehydrogenase (IMPDH); selective lymphocyte inhibition |
1–1.5 g BD (2–3 g/day) |
GI side effects (diarrhoea, nausea, abdominal pain), leucopenia, anaemia, thrombocytopenia, teratogenic |
Weekly FBC first month; reduce dose if WBC <3.5; counsel females re: contraception (teratogen); take with food to reduce GI effects |
| Prednisolone |
Corticosteroid — broad anti-inflammatory and immunosuppressive |
Taper: 20 mg → 10 mg → 5–7.5 mg/day by 3 months |
DM/hyperglycaemia, hypertension, osteoporosis, obesity, mood disturbance, adrenal suppression, infection, cataracts, avascular necrosis |
Never stop abruptly (adrenal crisis risk); sick day rules (double dose during illness/surgery); morning dosing; monitor glucose, BP, bone density |
| Ciclosporin (Neoral) — alternative CNI |
CNI — calcineurin inhibitor (same mechanism as tacrolimus) |
C0 (trough): 150–250 early / 75–150 late; or C2 (2h post-dose): 800–1200 early |
Hirsutism, gingival hyperplasia, nephrotoxicity, hypertension, tremor, hyperlipidaemia |
C2 level more sensitive than C0; consistent timing with meals; grapefruit contraindicated |
mTOR Inhibitors (Everolimus / Sirolimus)
Clinical Role
- Mechanism: mTOR pathway inhibition → antiproliferative (T-cell and tumour cells)
- CNI minimisation / withdrawal protocol: delay tacrolimus introduction or reduce CNI dose to protect kidney from CNI nephrotoxicity
- Also used in de novo malignancy post-transplant (antiproliferative effect)
- Sirolimus: original mTOR inhibitor; once daily; levels 4–12 ng/mL
- Everolimus: twice daily; levels 3–8 ng/mL
Side Effects & Precautions
- Impaired wound healing — must be held 6 weeks pre- and post-major surgery; surgical site complications, lymphocele
- Pneumonitis — interstitial lung disease; new respiratory symptoms require CT chest and drug cessation consideration
- Proteinuria — worsen pre-existing proteinuria; monitor urine PCR monthly
- Delayed wound healing, thrombocytopenia, hyperlipidaemia, mouth ulcers (aphthous stomatitis), peripheral oedema
- Not combined with ATG induction (synergistic over-immunosuppression)
Drug Interactions — Critical for GCC Nursing Exams
⚠
Azole Antifungals + Tacrolimus
Fluconazole, voriconazole, itraconazole markedly increase tacrolimus levels via CYP3A4 inhibition. When starting an azole, halve tacrolimus dose immediately and monitor levels daily. Tacrolimus toxicity (nephrotoxicity, neurotoxicity) can develop rapidly.
⚠
Grapefruit Juice — Absolute Contraindication
Grapefruit contains furanocoumarins that irreversibly inhibit CYP3A4 in intestinal wall → unpredictable increases in tacrolimus/ciclosporin/sirolimus levels. Patients must be explicitly counselled to avoid grapefruit and Seville orange juice.
Other Important Drug Interactions
| Interacting Drug | Effect on CNI Level | Nursing Action |
|---|
| Rifampicin (TB treatment) | Markedly DECREASES — CYP3A4 inducer | Up to 3–5× dose increase needed; daily monitoring; alert transplant team |
| St John's Wort | DECREASES — CYP3A4 inducer | Absolutely contraindicated; causes rejection episodes |
| Diltiazem / Verapamil | INCREASES — CYP3A4 inhibitor | Reduce CNI dose by ~30–50% when started |
| NSAIDs (ibuprofen etc.) | Additive nephrotoxicity with CNIs | Avoid NSAIDs; use paracetamol for analgesia |
| Statins | Increased statin levels (myopathy risk) | Use pravastatin or fluvastatin (less CYP interaction); monitor CK if muscle symptoms |
| Live vaccines | Contraindicated — risk of disseminated infection | No live vaccines (yellow fever, MMR, varicella, oral polio) post-transplant |
Cardiovascular Risk — Leading Cause of Post-Transplant Death
Cardiovascular Management
- Cardiovascular disease is the leading cause of death with functioning graft in renal transplant recipients
- Risk factors: Steroids → hypertension + dyslipidaemia; tacrolimus → NODAT + hypertension; underlying CKD + pre-existing CVD in ESRD patients
- BP target: <130/80 mmHg (KDIGO 2022)
- ACE inhibitors/ARBs: may be used but monitor for hyperkalaemia and creatinine rise; avoid early post-transplant (reduce renal perfusion)
- CCBs (amlodipine/nifedipine): first-line choice, well-tolerated with CNIs
- Statins: All transplant recipients with dyslipidaemia; pravastatin or fluvastatin preferred (less CYP3A4 interaction)
- Smoking cessation: mandatory counselling
- Annual cardiology review in high-risk patients
- BMI monitoring and lifestyle modification
- Home BP monitoring — educate on target, recording, and when to escalate
NODAT — New-Onset Diabetes After Transplantation
Risk & Screening
- Incidence: 20–50% within first year post-transplant
- Risk factors: tacrolimus (dose-dependent β-cell toxicity), steroids, obesity, family history, HCV co-infection, CMV infection, older age, South Asian / Arab ethnicity
- Screening: fasting glucose daily post-op, then weekly × 4, then monthly; HbA1c at 3 and 6 months
- Diagnosis: fasting glucose ≥7.0 mmol/L or 2h OGTT ≥11.1 mmol/L on 2 occasions
Management
- Initial: Insulin (most patients early post-transplant when glucose fluctuating and steroid dose high)
- As immunosuppression reduces (3–6 months): transition to oral agents where possible
- Tacrolimus dose reduction / conversion to ciclosporin may improve NODAT
- Dietary modification: low glycaemic index, regular meals, reduce refined carbohydrates
- GCC context: baseline high diabetes risk in Arab populations compounds NODAT risk significantly
Metabolic Bone Disease
Osteoporosis Prevention & Management
- Steroids accelerate bone loss — greatest in first 3–6 months (up to 10% bone mass lost)
- Pre-existing renal osteodystrophy from CKD/dialysis compounds the problem
- DEXA scan at transplant, 12 months, then every 2 years
- Calcium supplementation: 1000–1500 mg/day
- Vitamin D: Cholecalciferol (D3) 800–1000 IU/day; monitor 25-OH VitD levels
- Bisphosphonates (alendronate/risedronate): if T-score <-2.5 or high fracture risk; use with adequate renal function (eGFR >35)
- Weight-bearing exercise encouraged
De Novo Malignancy
★
Highest Priority: Skin Cancer Screening
Transplant recipients have a 50–100× increased risk of squamous cell carcinoma (SCC) compared to general population. SCC >> BCC (reverse of general population). Annual dermatology review is mandatory. Photoprotection is the single most important preventive measure to teach patients.
Skin Cancer
- SCC risk ≥100× general population; BCC risk elevated ~10×
- More aggressive behaviour, earlier metastasis
- Sun exposure is major modifiable risk factor — critical in GCC (high UV)
- SPF 50+ daily, protective clothing, sun avoidance 10am–4pm
- Annual dermatology review; self-examination monthly
- Consider switch to mTOR inhibitor if multiple skin lesions (antiproliferative benefit)
PTLD
- Post-Transplant Lymphoproliferative Disorder
- EBV-driven B-cell proliferation; risk highest in EBV D+/R− pairs
- Presentation: lymphadenopathy, fever, weight loss, extranodal disease
- Treatment: reduce immunosuppression ± rituximab ± chemotherapy
- Monitor EBV viral load in high-risk patients
Other Malignancies
- Bladder/urothelial cancer: increased risk; urine cytology if haematuria
- Cervical cancer (HPV-related): annual cervical smear; HPV vaccination pre-transplant if possible
- Breast cancer: standard mammography screening schedule maintained
- Kaposi's sarcoma: HHV-8 driven; common in Mediterranean and Arab populations
Patient Education — Priority Topics
Key Education Points for GCC Transplant Recipients
Daily Priorities
- Medication adherence: Most common cause of late rejection; never skip immunosuppression; same time daily; refill before running out
- BP home monitoring: Twice daily; keep diary; target <130/80; escalate if SBP >160
- Sun protection: SPF 50+, sun-protective clothing, avoid peak sun hours — highest priority in GCC climate
- Daily weight: gain >2 kg in 2 days → report (fluid retention, rejection)
Regular Screening
- Skin self-examination: Monthly; report any new lesions, non-healing sores, rapidly growing lumps
- Annual dermatology review: Non-negotiable in all transplant recipients
- Cervical smear: Annual (vs. 3-yearly in general population)
- Breast screening: Per national guidelines (annual mammogram from age 40 or per programme)
- Blood glucose monitoring (if NODAT or pre-diabetic)
GCC Transplant Programme Overview
Major GCC Transplant Centres
- KFSH&RC (King Faisal Specialist Hospital & Research Centre), Riyadh: Largest in MENA; >1000 renal transplants/year; established 1975; leading outcomes data
- King Khalid University Hospital / King Abdulaziz Medical City (NGHA): Major KSA programme
- Cleveland Clinic Abu Dhabi / SKMC (Sheikh Khalifa Medical City): UAE flagship programmes
- HMC (Hamad Medical Corporation), Doha: Qatar national programme
- KFHU Dammam, Saudi German Hospital: Additional KSA/UAE capacity
GCC-Specific Nursing Considerations
- High background rates of T2DM and hypertension → increased ESRD burden → high transplant demand
- Living related donation culturally preferred and Islamically accepted (majority fatwa); altruistic donation growing
- Expatriate populations (majority in UAE/Qatar) — insurance coverage and post-transplant follow-up after departure planning
- Ramadan — medication timing adjustments (tacrolimus: continue same interval; consult transplant team for timing optimisation); hydration challenges
- High UV index — skin cancer prevention education essential
- TB screening pre-transplant important in GCC context (reactivation risk)
Exam High-Yield Topics (DHA / DOH / SCFHS)
ⓘ
Tacrolimus Monitoring
Trough (C0) before morning dose. Early: 8–12, Late: 5–8. Azoles markedly increase levels. Grapefruit contraindicated. Daily monitoring post-transplant.
⚠
Acute Rejection Recognition
Creatinine rise ≥20% nadir + reduced UO + graft tenderness. Biopsy for Banff classification. Treatment: methylprednisolone 500mg IV × 3 days.
⚠
Vascular Thrombosis — Emergency
Sudden UO cessation 0–72h. Urgent Doppler USS. Emergency re-exploration. Time-critical — salvage requires rapid response.
★
BK Virus
Decoy cells in urine cytology. Over-immunosuppression. Treatment = reduce immunosuppression. BK PCR in blood to confirm nephropathy.
✓
Foley Catheter Duration
1–2 weeks post-transplant to protect ureteroneocystostomy. Irrigate if clots. Hourly UO measurement. Ureteric stent removed at 4–6 weeks.
⚠
Fluid Replacement Rule
Replace urine output mL for mL with 0.9% NaCl + 30–50 mL/h insensible. Hypovolaemia causes DGF. Avoid over-hydration in oliguria.
Practice MCQs — Renal Transplant Nursing
Post-Transplant Creatinine Trend Analyser